Novo Nordisk A/S’s EV / EBITDA at a glance
Novo Nordisk A/S reports ev / ebitda of 20.9x for Dec 2024. The prior period recorded 27.4x (Dec 2023). Year over year the metric moved −6.54 (−23.9%). The rolling three-period average stands at 25.4x. Data last refreshed Dec 7, 2025, 2:48 AM.
Latest reading
20.9x · Dec 2024
YoY movement
−6.54 (−23.9%)
Rolling average
25.4x
Current EV / EBITDA
20.9x
−6.54
−23.9%
Rolling average
25.4x
Latest Value
20.9x
Dec 2024
YoY Change
−6.54
Absolute
YoY Change %
−23.9%
Rate of change
3-Period Avg
25.4x
Smoothed
Narrative signal
Novo Nordisk A/S’s ev / ebitda stands at 20.9x for Dec 2024. Year-over-year, the metric shifted by −6.54, translating into a −23.9% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How ev / ebitda shapes Novo Nordisk A/S's story
As of Dec 2024, Novo Nordisk A/S reports ev / ebitda of 20.9x. Use EV/EBITDA to benchmark acquisition multiples, leverage-adjusted valuation, and comparable transaction ranges.
Why EV/EBITDA matters
It normalizes valuation across different leverage levels, making it a go-to metric for M&A and cross-company comparisons.
Watch for cyclical swings
EBITDA can swing with cycle-sensitive businesses. Track multi-year averages and peak vs. trough to understand value ranges.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Gross Margin
84.7%
Operating Margin
44.2%
Net Profit Margin
34.8%
Return on Equity
70.4%
Return on Assets
21.7%
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Novo Nordisk A/S (NVO) FAQs
Answers tailored to Novo Nordisk A/S’s ev / ebitda profile using the latest Financial Modeling Prep data.
What is Novo Nordisk A/S's current ev / ebitda?
As of Dec 2024, Novo Nordisk A/S reports ev / ebitda of 20.9x. This reading reflects the latest filings and price data for NVO.
How is Novo Nordisk A/S's ev / ebitda trending year over year?
Year-over-year, the figure shifts by −6.54 (−23.9%). Pair this context with revenue growth and free cash flow signals to gauge momentum for NVO.
Why does ev / ebitda matter for Novo Nordisk A/S?
The enterprise value to EBITDA ratio evaluates valuation relative to operating cash flow before capital structure impacts. For Novo Nordisk A/S, operating within Healthcare — Drug Manufacturers - General, tracking this metric helps benchmark management's execution against close competitors.
Is Novo Nordisk A/S's ev / ebitda above its recent average?
Novo Nordisk A/S's rolling three-period average sits at 25.4x. Comparing the latest reading of 20.9x to that baseline highlights whether momentum is building or fading for NVO.
How frequently is Novo Nordisk A/S's ev / ebitda refreshed?
Data for NVO was last refreshed on Dec 7, 2025, 2:48 AM and updates automatically every 24 hours, keeping your valuation inputs current.